Skip to content

Decheng Capital LLC

Follow

13F filer, CIK 2010850, MENLO PARK, CA

Decheng Capital LLC reported $685,065,734 across 11 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-13. Its ten largest share positions make up 99.89% of the portfolio.

Accepted , ingested 13F-HR 0001104659-26-127247

Period
2026-09-30
Reported value
$685M
Holdings
11
Top 10 weight
99.89%
New
0
Sold out
3

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RVMDexited-52,667-$9.86M
NAMSexited-176,887-$5.99M
RCUSreduced-39,700-$1.03M
TNGXexited-20,000-$625K
BYSIreduced-735,000-$566K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001104659-26-127247, largest first. % of portfolio is the value over $685,065,734, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
CGONCG ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 6,371,669 shares; 2025Q1: 6,371,669 shares; 2025Q2: 6,371,669 shares; 2025Q3: 6,371,669 shares; 2025Q4: 6,371,669 shares; 2026Q1: 6,371,669 shares; 2026Q2: 6,371,669 shares; 2026Q3: 6,371,669 shares 6,371,669$452M65.93%0Timeline
NUVBNUVATION BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 25,954,439 shares; 2025Q1: 25,954,439 shares; 2025Q2: 25,954,439 shares; 2025Q3: 25,954,439 shares; 2025Q4: 25,954,439 shares; 2026Q1: 25,954,439 shares; 2026Q2: 25,954,439 shares; 2026Q3: 25,954,439 shares 25,954,439$145M21.22%0Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,266,667 shares; 2025Q1: 4,041,736 shares; 2025Q2: 4,041,736 shares; 2025Q3: 4,041,736 shares; 2025Q4: 4,041,736 shares; 2026Q1: 4,041,736 shares; 2026Q2: 4,041,736 shares; 2026Q3: 4,041,736 shares 4,041,736$21.3M3.1%0Timeline
AARDAARDVARK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 3,917,299 shares; 2025Q2: 3,917,299 shares; 2025Q3: 3,917,299 shares; 2025Q4: 3,917,299 shares; 2026Q1: 3,917,299 shares; 2026Q2: 3,917,299 shares; 2026Q3: 3,917,299 shares 3,917,299$20.6M3.01%0Timeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,285,293 shares; 2025Q1: 3,285,293 shares; 2025Q2: 3,285,293 shares; 2025Q3: 3,285,293 shares; 2025Q4: 3,143,078 shares; 2026Q1: 2,724,868 shares; 2026Q2: 2,724,868 shares; 2026Q3: 2,724,868 shares 2,724,868$14.4M2.1%0Timeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 808,789 shares; 2025Q1: 808,789 shares; 2025Q2: 160,000 shares; 2025Q3: 547,609 shares; 2025Q4: 541,559 shares; 2026Q1: 477,819 shares; 2026Q2: 464,779 shares; 2026Q3: 425,079 shares 425,079$11M1.6%-39,700Timeline
EQEQUILLIUM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,447,308 shares; 2025Q1: 4,447,308 shares; 2025Q2: 4,447,308 shares; 2025Q3: 4,447,308 shares; 2025Q4: 4,447,308 shares; 2026Q1: 4,447,308 shares; 2026Q2: 4,447,308 shares; 2026Q3: 4,447,308 shares 4,447,308$7.23M1.05%0Timeline
LYELL IMMUNOPHARMA INCLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 11,909,341 shares; 2025Q1: 11,909,341 shares; 2025Q2: 595,466 shares; 2025Q3: 595,466 shares; 2025Q4: 692,050 shares; 2026Q1: 692,050 shares; 2026Q2: 692,050 shares; 2026Q3: 692,050 shares 692,050$6.78M0.99%0
ZNTLZENTALIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,338,095 shares; 2025Q1: 2,019,762 shares; 2025Q2: 1,323,327 shares; 2025Q3: 1,323,327 shares; 2025Q4: 1,323,327 shares; 2026Q1: 1,323,327 shares; 2026Q2: 1,323,327 shares; 2026Q3: 1,323,327 shares 1,323,327$3.67M0.54%0Timeline
BYSIBEYONDSPRING INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 4,882,651 shares; 2025Q1: 4,882,651 shares; 2025Q2: 4,531,481 shares; 2025Q3: 4,286,104 shares; 2025Q4: 3,800,702 shares; 2026Q1: 3,800,702 shares; 2026Q2: 3,800,702 shares; 2026Q3: 3,065,702 shares 3,065,702$2.36M0.34%-735,000Timeline
PYXSPYXIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 326,810 shares; 2025Q1: 326,810 shares; 2025Q2: 326,810 shares; 2025Q3: 326,810 shares; 2025Q4: 326,810 shares; 2026Q1: 326,810 shares; 2026Q2: 326,810 shares; 2026Q3: 326,810 shares 326,810$761K0.11%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RVMDREVOLUTION MEDICINES INC52,667$9.86Mshares
NAMSNEWAMSTERDAM PHARMA COMPANY176,887$5.99Mshares
TNGXTANGO THERAPEUTICS INC20,000$625Kshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-26-127247 base2026-11-13